Pharmaceutical Preparations · DE · CIK 1818794
Dyne Therapeutics develops targeted therapeutics for genetically driven neuromuscular diseases using its FORCE platform
Comparable business profile · signals at a glance
In the 90 days to Mar 11, 2026: 1 insider bought $84K · 4 sold $15.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 11, 2026 | Kersten DirkDirector | Sell | 129,672 | $19.52 | $2.5M |
| Mar 11, 2026 | Posner Brian SDirector | Buy | 2,000 | $19.35 | $39K |
| Mar 10, 2026 | Kersten DirkDirector | Sell | 281,858 | $19.80 | $5.6M |
| Mar 10, 2026 | Kersten DirkDirector | Sell | 219,758 | $19.33 | $4.2M |
| Mar 10, 2026 | Kersten DirkDirector | Sell | 9,482 | $18.21 | $173K |
| Mar 9, 2026 | Kersten DirkDirector | Sell | 177,690 | $17.72 | $3.1M |
| Mar 6, 2026 | Posner Brian SDirector | Buy | 3,000 | $15.06 | $45K |
| Mar 5, 2026 | Cox JohnCEO & President | Sell | 2,732 | $14.90 | $41K |
| Mar 5, 2026 | Kerr DouglasChief Medical Officer | Sell | 904 | $14.90 | $13K |
| Mar 5, 2026 | Friedl-Naderer JohannaChief Commercial Officer | Sell | 148 | $14.90 | $2K |
| Dec 5, 2025 | Cox JohnCEO & President | Sell | 2,662 | $20.72 | $55K |
| Dec 5, 2025 | Kerr DouglasChief Medical Officer | Sell | 880 | $20.72 | $18K |
| Dec 5, 2025 | Friedl-Naderer JohannaChief Commercial Officer | Sell | 144 | $20.72 | $3K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.